Showing 281 - 300 results of 5,484 for search '"Pharmaceutical"', query time: 0.07s Refine Results
  1. 281

    Under-reported relationship: a comparative study of pharmaceutical industry and patient organisation payment disclosures in the UK (2012–2016) by Piotr Ozieranski, Emily Rickard, Shai Mulinari, Marcell Csanádi

    Published 2020-09-01
    “…Objectives To examine the under-reporting of pharmaceutical company payments to patient organisations by donors and recipients.Design Comparative descriptive analysis of payments disclosed on drug company and charity regulator websites.Setting UK.Participants 87 donors (drug companies) and 425 recipients (patient organisations) reporting payments in 2012–2016.Main outcome measures Number and value of payments reported by donors and recipients; differences in reported payments from/to the same donors and recipients; payments reported in either dataset but not the other one; agreement between donor–recipient ties established by payments; overlap between donor and recipient lists and, respectively, industry and patient organisation data.Results Of 87 donors, 63 (72.4%) reported payments but 84 (96.6%) were mentioned by recipients. …”
    Get full text
    Article
  2. 282
  3. 283

    Development and Validation of an Ion-Pair HPLC-UV Method for the Quantitation of Quinoline and Indoloquinoline Alkaloids in Herbal and Pharmaceutical Antimalarial Formulations by Samuel Oppong Bekoe, Emmanuel Orman, Samuel Awenteka Adjabui, Abena Amponsaa Brobbey, James Oppong-Kyekyeku, Kwabena Frimpong-Manso Opuni, Noble Kuntworbe, Samuel Asare-Nkansah

    Published 2022-01-01
    “…An HPLC method targeting quinoline and indoloquinoline antimalarial alkaloids was developed, validated, and applied to evaluate herbal and pharmaceutical antimalarial formulations (HPAFs) and starting materials (APIs). …”
    Get full text
    Article
  4. 284
  5. 285
  6. 286

    Voluntary disclosures of payments from pharmaceutical companies to healthcare professionals in Germany: a descriptive study of disclosures in 2015 and 2016 by Marlene Stoll, Lara Hubenschmid, Cora Koch, Klaus Lieb

    Published 2020-09-01
    “…Objective To analyse voluntary payment reports of pharmaceutical companies to German healthcare professionals (HCPs) in 2015 and 2016 based on an industry-self-regulating transparency codex.Design and participants Cohort study of all German HCPs who voluntarily agreed that at least one payment they received in 2015 and 2016 from pharmaceutical companies is disclosed.Main outcome measures Number of HCPs who disclosed at least one payment in the database; separated by year of disclosure and whether they disclosed once or repeatedly. …”
    Get full text
    Article
  7. 287
  8. 288

    Development and Validation of a Precise Method for Determination of Benzalkonium Chloride (BKC) Preservative, in Pharmaceutical Formulation of Latanoprost Eye Drops by J. Mehta, K. Patidar, N. Vyas

    Published 2010-01-01
    “…The method was successfully applied for the determination of BKC in a pharmaceutical formulation of latanoprost ophthalmic solution without any interference from common excipients and drug substance. …”
    Get full text
    Article
  9. 289
  10. 290
  11. 291
  12. 292
  13. 293
  14. 294
  15. 295
  16. 296
  17. 297

    Efficient Removing of Pharmaceutical Contaminants of Commercial Carbamazepine by Natural Pyrite-Induced Fenton Reaction in a Wide pH Range by Tingting Shi, Jianjun Xi, Yidan Shao, Qiao Tong, Xi Zou, Hongping Zhou, Shourong Liu, Xiaoya Gao

    Published 2024-01-01
    “…Pharmaceutical contaminants are causing great attention for the public people, urgently requiring to be eliminated from the environment. …”
    Get full text
    Article
  18. 298
  19. 299

    A Localized Surface Plasmon Resonance Sensing Method for Simultaneous Determination of Atenolol and Amiloride in Pharmaceutical Dosage Forms and Urine Samples by Marwa R. El-Zahry

    Published 2018-01-01
    “…This contribution describes a simple, fast, and sensitive application of localized surface plasmon resonance effect of silver nanoparticles for simultaneous determination of antihypertensive drugs’ mixture atenolol and amiloride in both pharmaceutical dosage forms and in biological samples (urine). …”
    Get full text
    Article
  20. 300

    Influence of Process Parameters on Content Uniformity of a Low Dose Active Pharmaceutical Ingredient in a Tablet Formulation According to GMP by Muselík Jan, Franc Aleš, Doležel Petr, Goněc Roman, Krondlová Anna, Lukášová Ivana

    Published 2014-09-01
    “…The manufacturing process of directly compressed tablets containing the low dose active pharmaceutical ingredient (API) warfarin, with content uniformity passing validation criteria, is used as a model example. …”
    Get full text
    Article